Literature DB >> 29999557

Comprehensive molecular profiling of the B7 family in gastrointestinal cancer.

Qijie Zhao1, Fuyan Hu2, Zhangang Xiao1, Mingxing Li1, Xu Wu1, Yueshui Zhao1, Yuanlin Wu1, Jianhua Yin1, Ling Lin1, Hanyu Zhang1, Lingling Zhang1, Chi Hin Cho1,3, Jing Shen1.   

Abstract

OBJECTIVES: B7 family has been identified as co-stimulatory or co-inhibitory molecules on T-cell response and plays an important role in tumour mortality and malignancy. In this study, the expression pattern of B7 family in gastrointestinal (GI) cancer was examined. Its upstream regulating mechanism, downstream targets and association with clinical parameters were also studied.
MATERIALS AND METHODS: The expression level of B7 members was analysed by FIREHOUSE. The gene mutation, DNA methylation, association with clinical parameters and downstream network of B7 members were analysed in cBioportal. The mutation frequency was analysed by Catalogue of Somatic Mutations in Cancer (COSMIC) analysis. The phylogenetic tree was constructed in MEGA7. The interaction protein domain analysis was performed by Pfam 31.0.
RESULTS: Differential expression of B7 family molecules was detected in different kinds of GI cancer. High-frequency gene alteration was found in tumour samples. There was negative correlation of promoter methylation and mRNA expression of B7 family members in tumour samples, suggesting the epigenetic basis of B7 family gene deregulation in GI cancer. The overexpression of B7-H1 in pancreatic cancer, B7-H5 in oesophageal cancer and B7-H6 in liver cancer were significantly associated with worse overall survival. Finally, by network analysis, we identified some potential interacting proteins for B7-1/2 and B7-H1/DC.
CONCLUSIONS: Overall, our study suggested that B7 member deregulation was strongly involved in GI cancer tumorigenesis.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29999557      PMCID: PMC6528960          DOI: 10.1111/cpr.12468

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  70 in total

1.  Role of E542 and E545 missense mutations of PIK3CA in breast cancer: a comparative computational approach.

Authors:  D Thirumal Kumar; C George Priya Doss
Journal:  J Biomol Struct Dyn       Date:  2016-09-27

2.  The expression of B7-H3 and B7-H4 in human gallbladder carcinoma and their clinical implications.

Authors:  C-L Liu; X-X Zang; H Huang; H Zhang; C Wang; Y-L Kong; H-Y Zhang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2016-11       Impact factor: 3.507

3.  B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer.

Authors:  Yi Zhou; Yun Xu; Lujun Chen; Bin Xu; Changping Wu; Jingting Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

4.  B7-H3 and B7-H4 expression in non-small-cell lung cancer.

Authors:  Yuping Sun; Yunshan Wang; Jianqiang Zhao; Ming Gu; Ricardo Giscombe; Ann Kari Lefvert; Xiongbiao Wang
Journal:  Lung Cancer       Date:  2006-06-19       Impact factor: 5.705

5.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

6.  B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer.

Authors:  Lujun Chen; Haifeng Deng; Mingyang Lu; Bin Xu; Qi Wang; Jingting Jiang; Changping Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

7.  Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer.

Authors:  Xiao Song; Junwei Liu; Yi Lu; Hongchuan Jin; Dongsheng Huang
Journal:  Oncol Rep       Date:  2013-12-31       Impact factor: 3.906

Review 8.  CD8(+) T cells: foot soldiers of the immune system.

Authors:  Nu Zhang; Michael J Bevan
Journal:  Immunity       Date:  2011-08-26       Impact factor: 31.745

9.  B7-H4 is Predictive of Poor Prognosis in Patients with Gastric Cancer.

Authors:  YongHui Cui; ZhiHan Li
Journal:  Med Sci Monit       Date:  2016-11-07

10.  MMPP Attenuates Non-Small Cell Lung Cancer Growth by Inhibiting the STAT3 DNA-Binding Activity via Direct Binding to the STAT3 DNA-Binding Domain.

Authors:  Dong Ju Son; Jie Zheng; Yu Yeon Jung; Chul Ju Hwang; Hee Pom Lee; Ju Rang Woo; Song Yi Baek; Young Wan Ham; Min Woong Kang; Minho Shong; Gi Ryang Kweon; Min Jong Song; Jae Kyung Jung; Sang-Bae Han; Bo Yeon Kim; Do Young Yoon; Bu Young Choi; Jin Tae Hong
Journal:  Theranostics       Date:  2017-10-16       Impact factor: 11.556

View more
  5 in total

1.  Comprehensive molecular profiling of the B7 family in gastrointestinal cancer.

Authors:  Qijie Zhao; Fuyan Hu; Zhangang Xiao; Mingxing Li; Xu Wu; Yueshui Zhao; Yuanlin Wu; Jianhua Yin; Ling Lin; Hanyu Zhang; Lingling Zhang; Chi Hin Cho; Jing Shen
Journal:  Cell Prolif       Date:  2018-07-12       Impact factor: 6.831

2.  Shared genetic architecture and casual relationship between leptin levels and type 2 diabetes: large-scale cross-trait meta-analysis and Mendelian randomization analysis.

Authors:  Xinpei Wang; Jinzhu Jia; Tao Huang
Journal:  BMJ Open Diabetes Res Care       Date:  2020-04

Review 3.  Role of PD-L1 in Gut Mucosa Tolerance and Chronic Inflammation.

Authors:  Marina Chulkina; Ellen J Beswick; Irina V Pinchuk
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

4.  Constitutive programmed death ligand 1 expression protects gastric G-cells from Helicobacter pylori-induced inflammation.

Authors:  Michiel C Mommersteeg; Bing Ting Yu; Thierry P P van den Bosch; Johan H von der Thüsen; Ernst J Kuipers; Michael Doukas; Manon C W Spaander; Maikel P Peppelenbosch; Gwenny M Fuhler
Journal:  Helicobacter       Date:  2022-07-28       Impact factor: 5.182

Review 5.  Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development.

Authors:  Seyed Hossein Kiaie; Mohammad Javad Sanaei; Masoud Heshmati; Zahra Asadzadeh; Iman Azimi; Saleh Hadidi; Reza Jafari; Behzad Baradaran
Journal:  Acta Pharm Sin B       Date:  2020-12-15       Impact factor: 11.413

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.